Anteis S.A is a Swiss company, founded in 2003, specialised in modifying and functionalizing injectable hyaluronic acid for a range of medical applications.
Anteis has developed a new generation of hyaluronic acids using its dynamic cross-linking technology, an innovation that provides advantages in the fields of:
- Ophthalmology (Cataract, Glaucoma surgeries)
- Orthopaedics (Osteo-arthritis)
- Aesthetic (Wrinkle filler, Rehydration)
The company aims at diversifying its sources of revenues, through several ways of commercialisation:
- A distribution network in 90 countries, on 5 continents
- Direct-Sales
- B2B privileged partnerships
Safety, patient benefits, ethics, and innovation are the cornerstones of Anteis Aesthetic and healthcare solutions.
Anteis seeks to build-up strong and sustainable relationships with partners acting in the pharmaceutical, biotech, medtech industries in order to provide our practitioners and patients the most reliable, innovative and high-end products.
Through dedicated evaluation processes, the Business Development team will
consider with the deepest attention any of your proposals, and especially those concerning:
1. For its 3 fields of activities:
- National and regional exclusive distribution
- Extended supply and distribution through dedicated private label options
- In-Licensing any products and technologies
- Out-Licensing specific Anteis products, patents and technologies
2. Advanced Drug Delivery systems
Please contact our Business Development team atbusinessdev@anteis.com and they will promptly contact you back.
recommendprint this page top
